| Name | Title | Contact Details |
|---|
Kemberton is a leading provider of technology-enabled revenue cycle management services to hospitals for complex claims. We specialize in the management and collection of workers compensation, motor vehicle accident claims, veteran administration and the resolution of insurance denials for hospitals and physician practice groups. Kemberton helps accelerate collection times and maximize reimbursements for over 300 hospital clients across 35 states, resulting in over $1.5 billion dollars of incremental cash payments for our clients.
Knox Community Hospital is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Knox Community Hospital is based in Mount Vernon, OH. You can find more information on Knox Community Hospital at www.knoxcommhosp.org
American Medical Response (AMR) is a Englewood, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We aim to advance urologic patient care through bold innovation, based on diversity of thought, openness to new ideas, adaptation to change, integrity and compassion. We develop innovative therapies and participate in exceptional licensing opportunities. Our goal is to be the leading specialty company: recognized and trusted by patients and providers for our commitment to urology. Urologic conditions can have a major impact on daily life, with those affected often suffering in silence as their conditions are overlooked, misunderstood or not adequately treated.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.